Korea’s Fair Trade Commission Catches Samil Pharm Again For Illegal Rebates
This article was originally published in PharmAsia News
Executive Summary
Despite continuing government efforts to weed out kickbacks from pharma to doctors and hospitals, stopping the illegal practice has proved difficult.
You may also be interested in...
South Korean Fair Trade Commission Investigates Drug Makers For Offering Unethical Financial Incentives To Hospitals
SEOUL - South Korea's Fair Trade Commission is in the final stages of investigations into seven pharmaceutical companies including five foreign pharma companies in a series of complaints from civic groups that drug makers were offering financial incentives to hospitals and doctors to give priority to their products
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.